Interaction with FcγRIIB Is Critical for the Agonistic Activity of Anti-CD40 Monoclonal Antibody

被引:188
|
作者
White, Ann L. [1 ]
Chan, H. T. Claude [1 ]
Roghanian, Ali [1 ]
French, Ruth R. [1 ]
Mockridge, C. Ian [1 ]
Tutt, Alison L. [1 ]
Dixon, Sandra V. [1 ]
Ajona, Daniel [1 ]
Verbeek, J. Sjef [2 ]
Al-Shamkhani, Aymen [1 ]
Cragg, Mark S. [1 ]
Beers, Stephen A. [1 ]
Glennie, Martin J. [1 ]
机构
[1] Univ Southampton, Fac Med, Div Canc Sci, Southampton SO16 6YD, Hants, England
[2] Leiden Univ, Med Ctr, Dept Human Genet, NL-2333 ZA Leiden, Netherlands
来源
JOURNAL OF IMMUNOLOGY | 2011年 / 187卷 / 04期
关键词
C-RECEPTOR POLYMORPHISMS; T-CELL TOLERANCE; IN-VIVO; CD20; IMMUNOTHERAPY; CD40; PATHWAY; B-CELLS; LYMPHOMA; CANCER; THERAPY; TUMOR;
D O I
10.4049/jimmunol.1101135
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
A high activatory/inhibitory Fc gamma R binding ratio is critical for the activity of mAb such as rituximab and alemtuzumab that attack cancer cells directly and eliminate them by recruiting immune effectors. Optimal Fc gamma R binding profiles of other anti-cancer mAb, such as immunostimulatory mAb that stimulate or block immune receptors, are less clear. In this study, we analyzed the importance of isotype and Fc gamma R interactions in controlling the agonistic activity of the anti-mouse CD40 mAb 3/23. Mouse IgG1 (m1) and IgG2a (m2a) variants of the parental 3/23 (rat IgG2a) were engineered and used to promote humoral and cellular responses against OVA. The mouse IgG1 3/23 was highly agonistic and outperformed the parental Ab when promoting Ab (10-100-fold) and T cell (OTI and OTII) responses (2- to >10-fold). In contrast, m2a was almost completely inactive. Studies in Fc gamma R knockout mice demonstrated a critical role for the inhibitory Fc gamma RIIB in 3/23 activity, whereas activatory Fc gamma R (Fc gamma RI, -III, and -IV) was dispensable. In vitro experiments established that the stimulatory effect of Fc gamma RIIB was mediated through Ab cross-linking delivered in trans between neighboring cells and did not require intracellular signaling. Intriguingly, activatory Fc gamma R provided effective cross-linking of 3/23 m2a in vitro, suggesting the critical role of Fc gamma RIIB in vivo reflects its cellular distribution and bioavailability as much as its affinity for a particular Ab isotype. In conclusion, we demonstrate an essential cross-linking role for the inhibitory Fc gamma RIIB in anti-CD40 immunostimulatory activity and suggest that isotype will be an important issue when optimizing reagents for clinical use. The Journal of Immunology, 2011, 187: 1754-1763.
引用
收藏
页码:1754 / 1763
页数:10
相关论文
共 50 条
  • [1] Anti-CD40 monoclonal antibody
    Geldart, T
    Illidge, T
    LEUKEMIA & LYMPHOMA, 2005, 46 (08) : 1105 - 1113
  • [2] Therapeutic Activity of Agonistic, Human Anti-CD40 Monoclonal Antibodies Requires Selective FcγR Engagement
    Dahan, Rony
    Barnhart, Bryan C.
    Li, Fubin
    Yamniuk, Aaron P.
    Korman, Alan J.
    Ravetch, Jeffrey V.
    CANCER CELL, 2016, 29 (06) : 820 - 831
  • [3] Improved therapeutic activity of agonistic, human anti-CD40 monoclonal Abs by selective FcγR-engagement
    Dahan, Rony
    Barnhart, Bryan C.
    Korman, Alan J.
    Ravetch, Jeffrey V.
    CANCER IMMUNOLOGY RESEARCH, 2017, 5 (03)
  • [4] Improved therapeutic activity of agonistic, human anti-CD40 monoclonal Abs by selective Fc receptor-engagement
    Dahan, Rony
    Ravetch, Jeffrey V.
    CANCER IMMUNOLOGY RESEARCH, 2016, 4 (11)
  • [5] Characterization of a Broadly Reactive Anti-CD40 Agonistic Monoclonal Antibody for Potential Use as an Adjuvant
    Martin, Cameron
    Waghela, Suryakant D.
    Lokhandwala, Shehnaz
    Ambrus, Andy
    Bray, Jocelyn
    Vuong, Christina
    Vinodkumar, Vanitha
    Dominowski, Paul J.
    Rai, Sharath
    Mwangi, Duncan
    Foss, Dennis L.
    Mwangi, Waithaka
    PLOS ONE, 2017, 12 (01):
  • [6] Selective FcγR engagement by human agonistic anti-CD40 antibodies
    Ellmark, Peter
    Mangsbo, Sara M.
    Lindstedt, Malin
    TRANSLATIONAL CANCER RESEARCH, 2016, 5 : S839 - S841
  • [7] Identification of Fc mutations that optimize agonistic activity of human anti-CD40 monoclonal antibodies by enhancing appropriate Fcg receptor interactions
    Ye, Shiming
    Cohen, Diane
    Choi, Donghee
    Tan, Siu Sze
    Xiong, Joanna
    Akamatsu, Yoshiko
    Chao, Debra
    Hollenbaugh, Diane
    Harding, Fiona
    CANCER RESEARCH, 2018, 78 (13)
  • [8] Agonistic properties and in vivo antitumor activity of the anti-CD40 antibody SGN-14
    Francisco, JA
    Donaldson, KL
    Chace, D
    Siegall, CB
    Wahl, AF
    CANCER RESEARCH, 2000, 60 (12) : 3225 - 3231
  • [9] Preclinical antilymphoma activity of a humanized anti-CD40 monoclonal antibody, SGN-40
    Law, CL
    Gordon, KA
    Collier, J
    Klussman, K
    McEarchern, JA
    Cerveny, CG
    Mixan, BJ
    Lee, WP
    Lin, ZH
    Valdez, P
    Wahl, AF
    Grewal, IS
    CANCER RESEARCH, 2005, 65 (18) : 8331 - 8338
  • [10] Preclinical antitumor activity of a humanized anti-CD40 monoclonal antibody SGN-40.
    Law, CL
    Lee, WP
    Lin, ZH
    Grewal, IS
    Wahl, A
    BLOOD, 2003, 102 (11) : 646A - 646A